NSRX
Income statement / Annual
Last year (2024), Nasus Pharma Ltd.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Nasus Pharma Ltd.'s net income was -$1.53 M.
See Nasus Pharma Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
| Research and Development Expenses |
$335.00 K
|
$567.00 K
|
$1.12 M
|
| General & Administrative Expenses |
$743.00 K
|
$580.00 K
|
$926.00 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$743.00 K
|
$580.00 K
|
$926.00 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$1.08 M
|
$1.15 M
|
$2.04 M
|
| Cost And Expenses |
$1.08 M
|
$1.15 M
|
$2.04 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$29.00 K
|
$49.00 K
|
$18.00 K
|
| Depreciation & Amortization |
$0.00
|
$0.00
|
$0.00
|
| EBITDA |
-$1.52 M |
-$956.00 K |
-$2.13 M |
| EBITDA Ratio |
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$474.00 K
|
$142.00 K
|
-$110.00 K
|
| Income Before Tax |
-$1.55 M
|
-$1.01 M
|
-$2.15 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$1.53 M
|
-$1.05 M
|
-$1.71 M
|
| Net Income Ratio |
0
|
0
|
0
|
| EPS |
-0.17 |
-0.12 |
-0.19 |
| EPS Diluted |
-0.17 |
-0.12 |
-0.19 |
| Weighted Average Shares Out |
$9.06 M
|
$9.06 M
|
$9.06 M
|
| Weighted Average Shares Out Diluted |
$9.06 M
|
$9.06 M
|
$9.06 M
|
| Link |
|
|
|
